Description
Cabazitaxel is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.
Cabazitaxel in combination with prednisone is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment.
DOSAGE FORMS AND STRENGTHS
Single dose vial 60 mg/1.5 mL, supplied with diluent (5.7 mL) for JEVTANA
Pharma Services and Drug Inquiries
Our Pharma Division deals only with the best, GMP certified generics and branded medication for the export market. All our products are supported by strict adherence to quality and analysis certification.
Please note for the minimum order for Exports is of US$ 300. All orders will be subject to courier charges and supplies are normally dispatched through internationally accredited courier services.
Complete the form below to receive the no-obligation price quote.
Disclaimer
Note : We do not supply schedule-H (Example – narcotic drug or psychotropic drugs or anabolic steroids) and Anti- Abortion Drugs.
All Trademarks and Brands that appear on the website belong to their respective owners and South Delhi Pharma does not lay any claim on them we only provide Information. Following Information meant for Wholesalers, Suppliers, Exporters, Doctors, Comparator Supplies, Hospitals, Generic, Brand, Corporate Sourcing, reseller, and Pharmacies.
